v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
 6 Months Ended
Apr. 30, 2026
Apr. 30, 2025
CASH FLOWS FROM OPERATING ACTIVITIES    
Net loss $ (997,000) $ (2,634,000)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization expense 38,000 34,000
Amortization of OID and commitment fee discount – Promissory notes 4,000 12,000
Stock-based compensation 1,182,000 2,187,000
Gain on sale of Exotropin interests (390,000)
Change in obligation to repurchase shares (2,000)
Changes in operating assets and liabilities:    
Accounts receivable, net of allowance for bad debts (241,000) 183,000
Other receivable 2,000
Prepaid expenses (179,000) 3,000
Inventories (313,000) (2,000)
Accounts payable and accrued expenses 227,000 165,000
Security deposits (11,000)
Deferred revenue 73,000 (28,000)
Net cash used in operating activities (609,000) (78,000)
CASH FLOWS FROM INVESTING ACTIVITIES    
Purchase of fixed assets (78,000)
Proceeds from sale of Exotropin interests 376,000
Net cash provided by financing activities 298,000
CASH FLOWS FROM FINANCING ACTIVITIES    
Proceeds from sale of common stock 1,950,000
Payments on finance leases (14,000) (37,000)
Net cash provided by (used in) financing activities 1,936,000 (37,000)
Increase (decrease) in cash 1,625,000 (115,000)
Cash at beginning of period 221,000 657,000
Cash at end of period 1,846,000 542,000
SUPPLEMENTAL CASH FLOW INFORMATION:    
Cash paid for taxes
Cash paid for interest
NON-CASH INVESTING AND FINANCING TRANSACTIONS:    
Reduction in royalty payable through transfer of inventory 50,000
Reduction in liability from sale of Exotropin interests 14,000
Finance lease obligations $ 125,000